Caris Life Sciences, Inc. (CAI) on Thursday reported a sharp increase in fourth-quarter revenue and swung to profitability.
For the fourth quarter, revenue increased to $292.9 million from $129.9 million a year earlier. For the full year 2025, revenue rose to $812.0 million from $412.3 million in 2024.
The company posted net income of $82.0 million, or $0.28 per share, in the fourth quarter, compared with a net loss of $61.9 million, or $1.73 per share, a year earlier. For the full year 2025, net loss widened to $538.0 million, or $3.22 per share, compared with $378.3 million, or $10.66 per share, in the prior year.
For full-year 2026, Caris expects revenue in the range of $1.00 billion to $1.02 billion, representing growth of approximately 23% to 26% compared to 2025.
The company expects molecular profiling revenue to grow approximately 21% to 22% year over year in 2026, and pharma and research revenue to be in the range of $75 million to $85 million.
Caris also anticipates operating expenses of $590 million to $595 million in 2026 and expects to remain positive on free cash flow and adjusted EBITDA.
CAI is currently trading after market at $22.20, up $2.96 or 15.38 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.